2017_SBRT_Course Book

Systematic review: SRT & targeted drugs

Concerns of increased toxicity: Drug

SRT location Toxicity

Cetuximab

Head and neck

Mucositis, dermatitis, fistula

Sorafenib

Abdomen

Bleeding, bowel obstruction

Gefitinib, Erlotinib Thoracic

Pneumonitis

Bevacizumab

Abdominal

Ulcer, perforation

BRAF inhibitors Brain

Hemorrhage

• For many combinations, NO data available

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

43

/

DEGRO AG Stereotaxie Project: TOaSST Register Study of concomitant use of SRT and targeted drugs Eligibility criteria: • Treatment of any metastatic tumor with • Stereotactic radiotherapy • and any targeted drug (antibodies, small molecules, immunotherapy) • within + / - 4 weeks prior and after SBRT Primary endpoint:

• High grade toxicity > grade II Secondary endpoints: • OS, LC, DFS

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

44

/